Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 1.00 |
| ▸ | HTR3B | O95264 | 3/20 | 1.00 |
| ▸ | HTR3A | P46098 | 3/20 | 1.00 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 1.00 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.72 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bemesetron SCHEMBL5790539 | 1.00 | CYP2D6 (1.00) | CYP2D6HTR3EHTR3BHTR3AHTR3D | |
| Bemesetron SCHEMBL10765684 | 1.00 | CYP2D6 (1.00) | CYP2D6HTR3EHTR3BHTR3AHTR3D | |
| Bemesetron SCHEMBL195148 | 1.00 | CYP2D6 (1.00) | CYP2D6HTR3EHTR3BHTR3AHTR3D | |
| Bemesetron SCHEMBL29430183 | 1.00 | CYP2D6 (1.00) | CYP2D6HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5790401 | 0.86 | CYP2D6 (0.76) | CYP2D6HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5790402 | 0.86 | CYP2D6 (0.76) | CYP2D6HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL14685717 | 0.85 | CYP2D6 (0.97) | CYP2D6HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6504512 | 0.85 | CYP2D6 (0.97) | CYP2D6HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6504516 | 0.85 | CYP2D6 (0.97) | CYP2D6HTR3EHTR3BHTR3AHTR3D | |
| Tropanserin SCHEMBL467253 | 0.84 | CYP2D6 (1.00) | CYP2D6HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1098 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2024-11-07 | — | — | US | claimed |
| WO-2023016546-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2023-02-16 | — | — | WO | claimed |
| US-11547700-B2 | Compositions and methods for treating synucleinopathies | CHASE THERAPEUTICS CORPORATION (US) | 2023-01-10 | — | — | US | claimed |
| EP-3964206-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2022-03-09 | — | — | EP | claimed |
| EP-3691637-A1 | ORAL BENDAMUSTINE FORMULATIONS | TUBE Pharmaceuticals GmbH (AT) | 2020-08-12 | — | — | EP | claimed |
| US-20200246312-A1 | ORAL BENDAMUSTINE FORMULATIONS | TUBE PHARMACEUTICALS GMBH (AT) | 2020-08-06 | — | — | US | claimed |
| CN-111201019-A | Oral bendamustine formulations | 图贝药物有限公司 | 2020-05-26 | — | — | CN | claimed |
| WO-2019068904-A1 | ORAL BENDAMUSTINE FORMULATIONS | TUBE PHARMACEUTICALS GMBH (AT) | 2019-04-11 | — | — | WO | claimed |
| EP-2432467-B1 | SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF LESIONAL VESTIBULAR DISORDERS | INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECH MÉDICALE) (FR) | 2018-02-21 | — | — | EP | claimed |
| WO-2016118540-A1 | TREATING AND/OR PREVENTING EMESIS AND/OR NAUSEA INCLUDING ACUTE AND/OR DELAYED NAUSEA AND/OR EMESIS | Xoc Pharmaceuticals, Inc. (US) | 2016-07-28 | — | — | WO | claimed |
| EP-1140076-A1 | USE OF 5HT3-RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CHRONIC FATIGUE SYNDROME | Novartis Pharma GmbH (DE) | 2001-10-10 | — | — | EP | claimed |
| EP-1077704-A1 | COMBINATION THERAPY FOR TREATMENT OF DEPRESSION | ELI LILLY AND COMPANY (US) | 2001-02-28 | — | — | EP | claimed |
| WO-2000076500-A2 | COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION | RESPIRATORIUS AB (SE) | 2000-12-21 | — | — | WO | claimed |
| WO-2000037073-A1 | USE OF 5HT3-RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CHRONIC FATIGUE SYNDROME | NOVARTIS PHARMA GMBH (DE) | 2000-06-29 | — | — | WO | claimed |
| WO-1999059593-A1 | COMBINATION THERAPY FOR TREATMENT OF DEPRESSION | ELI LILLY AND COMPANY (US) | 1999-11-25 | — | — | WO | claimed |
| EP-0506813-A1 | 5-HT 3? ANTAGONISTS FOR TREATMENT OF NAUSEA, BRADYCARDIA OF HYPOTENSION ASSOCIATED WITH MYOCARDIAL INSTABILITY | Beecham Group p.l.c. (GB) | 1992-10-07 | — | — | EP | claimed |
| EP-0340270-B1 | 5-HT 3? RECEPTOR ANTAGONISTS FOR TREATMENT OF COUGH AND BRONCHOCONSTRICTION | BEECHAM GROUP PLC (GB) | 1992-07-15 | — | — | EP | claimed |
| WO-1991009593-A2 | 5-HT3 ANTAGONISTS FOR TREATMENT OF NAUSEA, BRADYCARDIA OF HYPOTENSION ASSOCIATED WITH MYOCARDIAL INSTABILITY | BEECHAM GROUP PLC (GB) | 1991-07-11 | — | — | WO | claimed |
| EP-0340270-A1 | 5-HT 3? RECEPTOR ANTAGONISTS FOR TREATMENT OF COUGH AND BRONCHOCONSTRICTION | BEECHAM GROUP PLC (GB) | 1989-11-08 | — | — | EP | claimed |
| WO-1989004660-A1 | 5-HT3 RECEPTOR ANTAGONISTS FOR TREATMENT OF COUGH AND BRONCHOCONSTRICTION | BEECHAM GROUP PLC (GB) | 1989-06-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | CYP2D6 1085/4885HTR3E 251/4885HTR3B 172/4885 |
| US-20200246312-A1 | ORAL BENDAMUSTINE FORMULATIONS | ABCB1, MTHFD1, BHMT | CYP2D6 292/4885HTR3E 2707/4885HTR3B 2601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.